Taipei Veterans General Hospital

Department of Pathology and Laboratory Medicine
No.201, Sec. 2, Shipai Rd., Beitou District, Taipei City, Taiwan
11217, R.O.C.
Tel: 02-2875-7449

Sample Information

Patient Name: 黃紫珍
Gender: Female
ID No.: N220231103
History No.: 30689339
Age: 53

Ordering Doctor: DOC3014F 陳育民
Ordering REQ.: C2193HK
Signing in Date: 2020/07/23

Path No.: S109-99747
MP No.: F20045
Assay: Oncomine Focus Assay
Sample Type: FFPE
Block No.: S109-19776A
Percentage of tumor cells: 20%
Note:

Sample Cancer Type: Non-Small Cell Lung Cancer

Table of Contents	Page

Report Highlights

3 Relevant Biomarkers
16 Therapies Available
199 Clinical Trials

Relevant Non-Small Cell Lung Cancer Findings

Gene	Finding	Gene	Finding
ALK	Not detected	NTRK1	Not detected
BRAF	Not detected	NTRK2	Not detected
EGFR	***EGFR p.(L858R) c.2573T>G***	NTRK3	Not detected
ERBB2	Not detected	RET	Not detected
KRAS	Not detected	ROS1	Not detected
MET	***MET amplification***		

Relevant Biomarkers

Indicated Contraindicated

Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
EGFR p.(L858R) c.2573T>G epidermal growth factor receptor Tier: IA Allele Frequency: 14.19%	**afatinib** [1, 2] **dacomitinib** [1, 2] **erlotinib** [1, 2] **gefitinib** [1, 2] **osimertinib** [1, 2] **bevacizumab* + erlotinib** [2] **erlotinib + ramucirumab** [2] afatinib + cetuximab atezolizumab + bevacizumab + chemotherapy gefitinib + chemotherapy bevacizumab + gefitinib	None	187
MET amplification MET proto-oncogene, receptor tyrosine kinase Tier: IA	crizotinib	None	18
AR amplification androgen receptor Tier: IIC	None	androgen receptor therapy bicalutamide leuprorelin	0

Public data sources included in relevant therapies: FDA1, NCCN, **EMA**2, ESMO
Tier Reference: Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.
*** Includes biosimilars**

Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)

DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect	Coverage
EGFR	p.(L858R)	c.2573T>G	COSM6224	chr7:55259515	14.19%	NM_005228.4	missense	1995

Copy Number Variations

Gene	Locus	Copy Number
MET	chr7:116313480	7.4
AR	chrX:66776186	6.45

Biomarker Descriptions

AR (androgen receptor)

Background: The AR gene encodes the androgen receptor protein (AR), a ligand-activated transcription factor regulated by the binding of the hormones testosterone and dihydrotestosterone[1,2]. Hormone binding to AR results in receptor dimerization, nuclear translocation, and target gene transcription, thus activating the RAS/RAF/MEK/ERK and PI3K/AKT/MTOR signaling pathways, which promote cell proliferation and survival[2,3,4].

Alterations and prevalence: Alterations in AR function can result from overexpression, gene amplification, or mutations. AR mutations, including L702H, W742C/L, H875Y, and T878A, are commonly observed in 10-30% of castration-resistant prostate cancer and result in decreased ligand specificity, allowing other nuclear hormones to activate AR[5]. Androgen receptor splice variants have been reported in castration resistant prostate cancer[6,7]. The androgen receptor splice variant 7 (AR-V7) is a result of aberrant mRNA splicing of AR exons 1-3 and a cryptic exon 3, resulting in the expression of a constitutively active protein[7].

Potential relevance: The FDA has granted fast track designation (2016) to seviteronel for AR-positive triple-negative breast cancer (TNBC) patients[8]. Androgen deprivation therapy (ADT) such as abiraterone[9] (2011) and enzalutamide[10] (2011) are FDA approved for use in locally advanced and metastatic prostate cancers. Although many men initially respond to ADT, most will develop hormone resistance. Resistance to ADT is also associated with other aberrations of the AR gene including mutations within the ligand binding domain and gene amplification[5,11,12]. The androgen receptor splice variant, AR-V7, lacks the ligand binding domain, resulting in constitutive activation and is associated with resistance to androgen deprivation therapy (ADT) in advanced prostate cancer[6].

EGFR (epidermal growth factor receptor)

Background: The EGFR gene encodes the epidermal growth factor receptor (EGFR) tyrosine kinase, a member of the human epidermal growth factor receptor (HER) family. Along with EGFR/ERBB1/HER1, ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4 make up the HER protein family[13]. EGFR ligand induced dimerization results in kinase activation and leads to stimulation of oncogenic signaling pathways including the PI3K/AKT/MTOR and RAS/RAF/MEK/ERK pathways. Activation of these pathways promote cell proliferation, differentiation, and survival[14,15].

Alterations and prevalence: Recurrent somatic mutations in the tyrosine kinase domain of EGFR are observed in approximately 10-20% of lung adenocarcinoma and at higher frequencies in never-smoker, female, and in Asian populations with lung cancer[16,17,18,19]. The most common mutations occur near the ATP-binding pocket of the kinase domain and include short in-frame deletions in exon 19 (EGFR exon 19 deletion) and the L858R amino acid substitution in exon 21[20]. These mutations constitutively activate the EGFR kinase resulting in downstream signaling and represent 80% of the EGFR mutations observed in lung cancer. A second group of recurrent activating mutations that are less common include E709K, G719X, S768I, L861Q, and short in-frame insertions in exon 20[21,22,23,24]. EGFR activating mutations in lung cancer tend to be mutually exclusive to KRAS activating mutations[25]. Although these variants are common in lung cancer, they are rare in other cancer types. In glioblastoma, recurrent activating EGFR mutations in the extracellular domain include R108K, A289V and G598V[20,26]. The recurrent focal amplification of the EGFR gene leads to an increase in expression in several cancer types. EGFR is amplified in up to 30% of glioblastoma, 12% of esophageal cancer, 10% of head and neck cancer, 5% of bladder cancer, and 5% of lung squamous cell carcinoma[17,18,19,26,27]. Deletion of exons 2-7 encoding the extracellular domain of EGFR (EGFRvIII) results in overexpression of a ligand-independent constitutively active protein which is frequently observed in glioblastoma and has been shown to lead to lung cancer development as well as sensitivity to TKIs[28,29,30].

Potential relevance: Erlotinib[31] (2004), afatinib[32] (2013), gefitinib[33] (2015), osimertinib[34] (2015), and dacomitinib[35] (2018) are small molecule TKIs that are FDA approved for non-small cell lung cancer (NSCLC) patients with sensitizing exon 19 deletions and exon 21 L858R mutations. Acquired secondary mutations often confer resistance to first line TKI therapy with the T790M amino acid substitution accounting for 50-60% of cases[20]. Osimertinib is also indicated for NSCLC patients harboring EGFR T790M mutations whose disease has progressed on or after treatment with a first line TKI. EGFR targeting antibodies including cetuximab[36] (2004), panitumumab[37] (2006), and necitumumab[38] (2016) are also under investigation in combination with EGFR-targeting TKIs for efficacy against EGFR mutations. The use of cetuximab in combination with afatinib is currently recommended by the NCCN for patients who have progressed after receiving erlotinib, afatinib, dacomitinib, or gefitinib and chemotherapy[39].

Biomarker Descriptions (continued)

MET (MET proto-oncogene, receptor tyrosine kinase)

Background: The MET proto-oncogene encodes a receptor tyrosine kinase for the hepatocyte growth factor (HGF) protein, which is expressed by mesenchymal cells. Ubiquitin-dependent proteolysis regulates the steady state level of the MET protein via recognition of the tyrosine phosphorylation site Y1003 in the MET Cbl-binding domain within the juxtamembrane region[40,41,42]. Growth factor signaling leads to MET dimerization and subsequent initiation of downstream effectors including those involved in the RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways, which regulate cell migration, proliferation, and survival[43,44].

Alterations and prevalence: Recurrent somatic MET alterations include activating mutations, gene amplification, and translocations generating MET gene fusions. Recurrent somatic mutations fall into two classes, mutations in the MET kinase domain, which are uncommon, and splice-site mutations affecting exon 14. Recurrent kinase domain mutations are observed in papillary renal cell carcinoma (PRCC) (1-2%) and include M1250T, H1094Y, and V1070E. Mutation of the Y1003 phosphorylation site is reported in lung cancer but is uncommon (<1%)[19,26]. In contrast, splice-site mutations flanking exon 14 are observed in 4% of non-small cell lung cancer (NSCLC). These mutations include canonical splice site mutations affecting exon 14 and deletions that extend into the splicing motifs within intron 13[45,46]. Such mutations disrupt splicing leading to the formation of an alternative transcript that joins exon 13 directly to exon 15 and skips exon 14 entirely. The MET exon 14 skipping transcript lacks the juxtamembrane domain that contains the recognition motif for ubiquitin-dependent proteolysis and thus leads to a marked increase in steady-state level of the MET protein[47]. MET exon 14 skipping mutations act as oncogenic drivers in lung cancer mutually exclusive to activating mutations in EGFR and KRAS and other oncogenic fusions such as ALK and ROS1[45,48,49]. MET is amplified in 2-5% of ovarian cancer, esophageal adenocarcinoma, stomach adenocarcinoma, glioblastoma, and lung adenocarcinoma[19,26,50]. Recurrent MET fusions, although infrequent, are observed in adult and pediatric glioblastoma, papillary renal cell carcinoma, lung cancer, liver cancer, thyroid cancer, and melanoma[51,52,53]. MET alterations are believed to be enriched in late-stage cancers where they drive tumor progression and metastasis[54,55,56].

Potential relevance: The FDA has granted designations for two investigational MET inhibitors— capmatinib[57] has been granted FDA orphan drug and breakthrough therapy designations for MET exon 14 skipping positive metastatic NSCLC following platinum-based chemotherapy, and tepotinib[58] has been granted FDA breakthrough designation (2019) for advanced MET exon 14 skipping NSCLC. MET exon 14 skipping mutations confer sensitivity to approved kinase inhibitors including crizotinib (2011), which is recommended for MET amplifications and exon 14 skipping mutations[39,45,48,49]. Conversely, amplification of MET has been observed to mediate resistance to EGFR tyrosine kinase inhibitors (TKIs)[59,60,61,62,63]. In a phase II trial testing the MET inhibitor savolitinib, patients with advanced PRCC exhibited median progression free survival (PFS) of 6.2 and 1.4 months for MET-driven and MET-independent PRCC, respectively[64].

Relevant Therapy Summary

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

EGFR p.(L858R) c.2573T>G

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
afatinib	●	●	●	●	● (IV)
gefitinib	●	●	●	●	● (IV)
erlotinib	●	●	●	●	● (III)
osimertinib	●	●	●	●	● (III)
dacomitinib	●	●	●	●	✖

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

EGFR p.(L858R) c.2573T>G (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
bevacizumab + erlotinib	✖	●	●	●	● (II)
erlotinib + ramucirumab	✖	●	●	●	✖
afatinib + cetuximab	✖	●	✖	✖	✖
bevacizumab (Allergan) + erlotinib	✖	✖	●	✖	✖
atezolizumab + bevacizumab + carboplatin + paclitaxel	✖	✖	✖	●	✖
bevacizumab + gefitinib	✖	✖	✖	●	✖
gefitinib + carboplatin + pemetrexed	✖	✖	✖	●	✖
anlotinib hydrochloride, toripalimab	✖	✖	✖	✖	● (IV)
apatinib + EGFR tyrosine kinase inhibitor	✖	✖	✖	✖	● (IV)
apatinib + gefitinib	✖	✖	✖	✖	● (IV)
bevacizumab + osimertinib, osimertinib	✖	✖	✖	✖	● (IV)
EGFR tyrosine kinase inhibitor	✖	✖	✖	✖	● (IV)
erlotinib, gefitinib, icotinib hydrochloride, chemotherapy	✖	✖	✖	✖	● (IV)
gefitinib, radiation therapy	✖	✖	✖	✖	● (IV)
icotinib hydrochloride	✖	✖	✖	✖	● (IV)
icotinib hydrochloride, icotinib hydrochloride + chemotherapy	✖	✖	✖	✖	● (IV)
icotinib hydrochloride, radiation therapy	✖	✖	✖	✖	● (IV)
ASK120067, gefitinib	✖	✖	✖	✖	● (III)
bevacizumab (Shanghai Hengrui Pharmaceutical) + chemotherapy, bevacizumab + chemotherapy	✖	✖	✖	✖	● (III)
bevacizumab, atezolizumab, chemotherapy	✖	✖	✖	✖	● (III)
bevacizumab, erlotinib	✖	✖	✖	✖	● (III)
BPI-7711, gefitinib	✖	✖	✖	✖	● (III)
durvalumab, chemotherapy	✖	✖	✖	✖	● (III)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

EGFR p.(L858R) c.2573T>G (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
erlotinib, chemotherapy	✖	✖	✖	✖	● (III)
erlotinib, erlotinib + chemotherapy	✖	✖	✖	✖	● (III)
gefitinib + chemotherapy	✖	✖	✖	✖	● (III)
gefitinib, anlotinib hydrochloride	✖	✖	✖	✖	● (III)
gefitinib, apatinib	✖	✖	✖	✖	● (III)
gefitinib, chemotherapy	✖	✖	✖	✖	● (III)
gefitinib, erlotinib	✖	✖	✖	✖	● (III)
gefitinib, erlotinib, gefitinib + radiation therapy, erlotinib + radiation therapy	✖	✖	✖	✖	● (III)
gefitinib, icotinib hydrochloride, erlotinib, gefitinib + radiation therapy, icotinib hydrochloride + radiation therapy, erlotinib + radiation therapy	✖	✖	✖	✖	● (III)
HS-10296, gefitinib	✖	✖	✖	✖	● (III)
icotinib hydrochloride, chemotherapy	✖	✖	✖	✖	● (III)
icotinib hydrochloride, icotinib hydrochloride + radiation therapy	✖	✖	✖	✖	● (III)
nivolumab, chemotherapy	✖	✖	✖	✖	● (III)
osimertinib, chemotherapy	✖	✖	✖	✖	● (III)
pembrolizumab, chemotherapy	✖	✖	✖	✖	● (III)
AZD-3759, erlotinib, gefitinib	✖	✖	✖	✖	● (II/III)
afatinib + DFP-14323, erlotinib + DFP-14323, osimertinib + DFP-14323	✖	✖	✖	✖	● (II)
afatinib, bevacizumab	✖	✖	✖	✖	● (II)
afatinib, chemotherapy, radiation therapy	✖	✖	✖	✖	● (II)
anlotinib hydrochloride + icotinib hydrochloride	✖	✖	✖	✖	● (II)
anlotinib hydrochloride, erlotinib, icotinib hydrochloride, gefitinib	✖	✖	✖	✖	● (II)
atezolizumab, chemotherapy	✖	✖	✖	✖	● (II)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

EGFR p.(L858R) c.2573T>G (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
bevacizumab + gefitinib + chemotherapy	✖	✖	✖	✖	● (II)
bevacizumab, erlotinib, chemotherapy	✖	✖	✖	✖	● (II)
bevacizumab, osimertinib	✖	✖	✖	✖	● (II)
bintrafusp alfa, chemoradiation therapy, durvalumab	✖	✖	✖	✖	● (II)
chemotherapy, atezolizumab, bevacizumab	✖	✖	✖	✖	● (II)
chemotherapy, ramucirumab	✖	✖	✖	✖	● (II)
crizotinib + chemotherapy	✖	✖	✖	✖	● (II)
durvalumab, tremelimumab, chemotherapy	✖	✖	✖	✖	● (II)
EGFR tyrosine kinase inhibitor + chemotherapy	✖	✖	✖	✖	● (II)
EGFR tyrosine kinase inhibitor + chemotherapy, EGFR tyrosine kinase inhibitor	✖	✖	✖	✖	● (II)
EGFR tyrosine kinase inhibitor, radiation therapy	✖	✖	✖	✖	● (II)
erlotinib + chemotherapy	✖	✖	✖	✖	● (II)
erlotinib + surgical intervention	✖	✖	✖	✖	● (II)
erlotinib, bevacizumab + erlotinib	✖	✖	✖	✖	● (II)
erlotinib, gefitinib	✖	✖	✖	✖	● (II)
erlotinib, radiation therapy	✖	✖	✖	✖	● (II)
famitinib, HS-10296	✖	✖	✖	✖	● (II)
gefitinib + fulvestrant	✖	✖	✖	✖	● (II)
gefitinib + nazartinib	✖	✖	✖	✖	● (II)
gefitinib, surgical intervention	✖	✖	✖	✖	● (II)
gefitinib, thalidomide	✖	✖	✖	✖	● (II)
icotinib hydrochloride + radiation therapy	✖	✖	✖	✖	● (II)
icotinib hydrochloride + radiation therapy, icotinib hydrochloride	✖	✖	✖	✖	● (II)
nivolumab, ipilimumab	✖	✖	✖	✖	● (II)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

EGFR p.(L858R) c.2573T>G (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
osimertinib + radiation therapy	✖	✖	✖	✖	● (II)
osimertinib + selumetinib	✖	✖	✖	✖	● (II)
osimertinib, afatinib	✖	✖	✖	✖	● (II)
osimertinib, bevacizumab	✖	✖	✖	✖	● (II)
osimertinib, gefitinib + osimertinib	✖	✖	✖	✖	● (II)
osimertinib, radiation therapy	✖	✖	✖	✖	● (II)
osimertinib, ramucirumab	✖	✖	✖	✖	● (II)
osimertinib, savolitinib	✖	✖	✖	✖	● (II)
pembrolizumab + chemotherapy	✖	✖	✖	✖	● (II)
poziotinib	✖	✖	✖	✖	● (II)
ramucirumab, osimertinib	✖	✖	✖	✖	● (II)
tepotinib, osimertinib	✖	✖	✖	✖	● (II)
tyrosine kinase inhibitors, radiation therapy	✖	✖	✖	✖	● (II)
zoledronic acid, gefitinib	✖	✖	✖	✖	● (II)
AZD-3759	✖	✖	✖	✖	● (I/II)
bevacizumab + erlotinib + chemotherapy	✖	✖	✖	✖	● (I/II)
CBT-502, anlotinib hydrochloride	✖	✖	✖	✖	● (I/II)
DZD-9008	✖	✖	✖	✖	● (I/II)
EMB01	✖	✖	✖	✖	● (I/II)
erlotinib + trametinib	✖	✖	✖	✖	● (I/II)
gefitinib + osimertinib	✖	✖	✖	✖	● (I/II)
icotinib hydrochloride + chemotherapy + radiation therapy	✖	✖	✖	✖	● (I/II)
KP-673	✖	✖	✖	✖	● (I/II)
lazertinib	✖	✖	✖	✖	● (I/II)
ningetinib, gefitinib	✖	✖	✖	✖	● (I/II)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

EGFR p.(L858R) c.2573T>G (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
oleclumab + osimertinib	✖	✖	✖	✖	● (I/II)
S-49076, gefitinib	✖	✖	✖	✖	● (I/II)
telaglenastat, osimertinib	✖	✖	✖	✖	● (I/II)
U3-1402	✖	✖	✖	✖	● (I/II)
afatinib, chemotherapy	✖	✖	✖	✖	● (I)
afatinib, immunostimulant	✖	✖	✖	✖	● (I)
afatinib, osimertinib	✖	✖	✖	✖	● (I)
alisertib, osimertinib	✖	✖	✖	✖	● (I)
anlotinib hydrochloride + erlotinib	✖	✖	✖	✖	● (I)
CK-101	✖	✖	✖	✖	● (I)
dacomitinib, osimertinib	✖	✖	✖	✖	● (I)
DS-1205c, gefitinib	✖	✖	✖	✖	● (I)
DS-1205c, osimertinib	✖	✖	✖	✖	● (I)
EGFR tyrosine kinase inhibitor, anlotinib hydrochloride	✖	✖	✖	✖	● (I)
everolimus + neratinib, neratinib + palbociclib, neratinib + trametinib	✖	✖	✖	✖	● (I)
genolimzumab, fruquintinib	✖	✖	✖	✖	● (I)
JNJ-61186372	✖	✖	✖	✖	● (I)
lazertinib, JNJ-61186372	✖	✖	✖	✖	● (I)
nazartinib + trametinib, nazartinib + ribociclib, LXH254 + nazartinib, capmatinib + nazartinib, gefitinib + nazartinib	✖	✖	✖	✖	● (I)
niraparib, osimertinib	✖	✖	✖	✖	● (I)
nivolumab, ipilimumab, radiation therapy	✖	✖	✖	✖	● (I)
osimertinib + radiation therapy, osimertinib	✖	✖	✖	✖	● (I)
osimertinib, necitumumab	✖	✖	✖	✖	● (I)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

EGFR p.(L858R) c.2573T>G (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
osimertinib, sapanisertib	✖	✖	✖	✖	● (I)
pirotinib	✖	✖	✖	✖	● (I)
SH-1028	✖	✖	✖	✖	● (I)
telisotuzumab vedotin, osimertinib	✖	✖	✖	✖	● (I)
TNO-155	✖	✖	✖	✖	● (I)
TP-0903	✖	✖	✖	✖	● (I)
tyrosine kinase inhibitors, tyrosine kinase inhibitors + chemotherapy	✖	✖	✖	✖	● (I)

MET amplification

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
crizotinib	✖	●	✖	✖	● (II)
cabozantinib	✖	✖	✖	✖	● (II)
capmatinib	✖	✖	✖	✖	● (II)
osimertinib, savolitinib	✖	✖	✖	✖	● (II)
telisotuzumab vedotin	✖	✖	✖	✖	● (II)
tepotinib, osimertinib	✖	✖	✖	✖	● (II)
OMO-1	✖	✖	✖	✖	● (I/II)
REGN-5093	✖	✖	✖	✖	● (I/II)
S-49076, gefitinib	✖	✖	✖	✖	● (I/II)
glumetinib	✖	✖	✖	✖	● (I)
JNJ-61186372	✖	✖	✖	✖	● (I)
metatinib	✖	✖	✖	✖	● (I)
TPX-0022	✖	✖	✖	✖	● (I)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

AR amplification

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
androgen receptor therapy	✖	○	✖	✖	✖
bicalutamide	✖	○	✖	✖	✖
leuprorelin	✖	○	✖	✖	✖

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Details

Current FDA Information

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated 👎 Not recommended 🛡 Resistance

FDA information is current as of 2020-02-28. For the most up-to-date information, search www.fda.gov.

EGFR p.(L858R) c.2573T>G

● **afatinib**

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2019-10-11 **Variant class:** EGFR L858R mutation

Indications and usage:

GILOTRIF® is a kinase inhibitor indicated for:

- First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.

Limitation of Use: Safety and efficacy of GILOTRIF® were not established in patients whose tumors have resistant EGFR mutations

- Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf

EGFR p.(L858R) c.2573T>G (continued)

dacomitinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2018-09-27 **Variant class:** EGFR L858R mutation

Indications and usage:
VIZIMPRO® is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf

erlotinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2016-10-18 **Variant class:** EGFR L858R mutation

Indications and usage:

TARCEVA® is a kinase inhibitor indicated for:

- The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.
- First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.

Limitations of Use:

- Safety and efficacy of TARCEVA® have not been established in patients with NSCLC whose tumors have other EGFR mutations.
- TARCEVA® is not recommended for use in combination with platinum-based chemotherapy.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf

gefitinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2018-08-22 **Variant class:** EGFR L858R mutation

Indications and usage:

IRESSA® is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

Limitation of Use: Safety and efficacy of IRESSA® have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206995s003lbl.pdf

EGFR p.(L858R) c.2573T>G (continued)

osimertinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2019-12-19 **Variant class:** EGFR L858R mutation

Indications and usage:

TAGRISSO® is a kinase inhibitor indicated for

- the first-line treatment of patients with metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
- the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208065s013lbl.pdf

Current NCCN Information

In this cancer type | In other cancer type | In this cancer type and other cancer types | Contraindicated | Not recommended | Resistance

NCCN information is current as of 2019-11-01. For the most up-to-date information, search www.nccn.org.
For NCCN International Adaptations & Translations, search www.nccn.org/global/international_adaptations.aspx.

EGFR p.(L858R) c.2573T>G

afatinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR L858R mutation

NCCN Recommendation category: 1

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Sensitizing EGFR mutation discovered prior to first-line systemic therapy (First-line therapy) (Other Recommended)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

dacomitinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR L858R mutation

NCCN Recommendation category: 1

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Sensitizing EGFR mutation discovered prior to first-line systemic therapy (First-line therapy) (Other Recommended)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

erlotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR L858R mutation

NCCN Recommendation category: 1

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Sensitizing EGFR mutation discovered prior to first-line systemic therapy (First-line therapy) (Other Recommended)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

EGFR p.(L858R) c.2573T>G (continued)

gefitinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR L858R mutation

NCCN Recommendation category: 1

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Sensitizing EGFR mutation discovered prior to first-line systemic therapy (First-line therapy) (Other Recommended)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

osimertinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR L858R mutation

NCCN Recommendation category: 1

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Sensitizing EGFR mutation discovered prior to first-line systemic therapy (First-line therapy) (Preferred)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

afatinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR L858R mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Sensitizing EGFR mutation discovered during first-line systemic therapy; Interrupt or complete planned systemic therapy, including maintenance therapy (First-line therapy)
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Progression after first-line therapy (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

bevacizumab + erlotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR L858R mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Non-Squamous Non-Small Cell Lung Cancer; Progression after first-line therapy (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

EGFR p.(L858R) c.2573T>G (continued)

dacomitinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR L858R mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Sensitizing EGFR mutation discovered during first-line systemic therapy; Interrupt or complete planned systemic therapy, including maintenance therapy (First-line therapy)
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Progression after first-line therapy (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

erlotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR L858R mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Sensitizing EGFR mutation discovered during first-line systemic therapy; Interrupt or complete planned systemic therapy, including maintenance therapy (First-line therapy)
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Progression after first-line therapy (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

erlotinib + ramucirumab

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR L858R mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Sensitizing EGFR mutation discovered prior to first-line systemic therapy (First-line therapy) (Other Recommended)
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Sensitizing EGFR mutation discovered during first-line systemic therapy (First-line therapy)
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Progression after first-line therapy (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

EGFR p.(L858R) c.2573T>G (continued)

gefitinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR L858R mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Sensitizing EGFR mutation discovered during first-line systemic therapy; Interrupt or complete planned systemic therapy, including maintenance therapy (First-line therapy)
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Progression after first-line therapy (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

osimertinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR L858R mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Adenocarcinoma, Large Cell, Non-Small Cell Lung Cancer (NOS), Squamous Cell Carcinoma; Sensitizing EGFR mutation discovered during first-line systemic therapy; Interrupt or complete planned systemic therapy, including maintenance therapy (First-line therapy) (Preferred)
- Progression on osimertinib (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

bevacizumab + erlotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR L858R mutation

NCCN Recommendation category: 2B

Population segment (Line of therapy):
- Non-Squamous Non-Small Cell Lung Cancer; Sensitizing EGFR mutation discovered prior to first-line systemic therapy (First-line therapy) (Useful in Certain Circumstances)
- Non-Squamous Non-Small Cell Lung Cancer; Sensitizing EGFR mutation discovered during first-line systemic therapy (First-line therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

EGFR p.(L858R) c.2573T>G (continued)

erlotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR L858R mutation

NCCN Recommendation category: 2B

Population segment (Line of therapy):
- Non-Small Cell Lung Cancer; Leptomeningeal and Spine metastases; Weekly pulse erlotinib (Not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 3.2019]

---

afatinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Non-Small Cell Lung Cancer; Brain metastases; Recurrent disease; Use agents active against primary tumor (Not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 3.2019]

---

afatinib + cetuximab

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

Other criteria: EGFR T790M negative

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Non-Small Cell Lung Cancer; Progression after receiving erlotinib, afatinib, dacomitinib, or gefitinib and systemic therapy (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

---

erlotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Non-Small Cell Lung Cancer; Brain metastases; Recurrent disease; Use agents active against primary tumor (Not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 3.2019]

EGFR p.(L858R) c.2573T>G (continued)

gefitinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Non-Small Cell Lung Cancer; Brain metastases; Recurrent disease; Use agents active against primary tumor (Not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 3.2019]

osimertinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Non-Small Cell Lung Cancer; Brain metastases; Newly diagnosed (Not specified)
- Non-Small Cell Lung Cancer; Leptomeningeal and Spine metastases (Not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 3.2019]

alectinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "Likewise, crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib are not recommended for patients with sensitizing EGFR mutations who relapse on EGFR TKI therapy."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

brigatinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "Likewise, crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib are not recommended for patients with sensitizing EGFR mutations who relapse on EGFR TKI therapy."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

EGFR p.(L858R) c.2573T>G (continued)

ceritinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "Likewise, crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib are not recommended for patients with sensitizing EGFR mutations who relapse on EGFR TKI therapy."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

crizotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "Likewise, crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib are not recommended for patients with sensitizing EGFR mutations who relapse on EGFR TKI therapy."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

lorlatinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "Likewise, crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib are not recommended for patients with sensitizing EGFR mutations who relapse on EGFR TKI therapy."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

pembrolizumab

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR mutation

Other criteria: CD274 overexpression

Summary:
NCCN Guidelines® include the following supporting statement(s):
- "A small study suggests that single-agent pembrolizumab is not effective as first-line therapy in patients with metastatic NSCLC and EGFR mutations, even those with PD-L1 levels more than 50%."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

MET amplification

● crizotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** MET amplification

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Non-Small Cell Lung Cancer; High-level MET amplification; Emerging targeted agents

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]

AR amplification

○ androgen receptor therapy

Cancer type: Head and Neck Cancer **Variant class:** AR positive

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Recurrent Metastatic Salivary Gland Tumors; Distant metastases; PS 0-3 (Therapy for recurrence)

Reference: NCCN Guidelines® - NCCN-Head and Neck Cancers [Version 3.2019]

○ bicalutamide

Cancer type: Head and Neck Cancer **Variant class:** AR positive

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Recurrent Metastatic Salivary Gland Tumors; Distant metastases; PS 0-3 (Therapy for recurrence)

Reference: NCCN Guidelines® - NCCN-Head and Neck Cancers [Version 3.2019]

○ leuprorelin

Cancer type: Head and Neck Cancer **Variant class:** AR positive

NCCN Recommendation category: 2A

Population segment (Line of therapy):
- Recurrent Metastatic Salivary Gland Tumors; Distant metastases; PS 0-3 (Therapy for recurrence)

Reference: NCCN Guidelines® - NCCN-Head and Neck Cancers [Version 3.2019]

Current EMA Information

In this cancer type | In other cancer type | In this cancer type and other cancer types | Contraindicated | Not recommended | Resistance

EMA information is current as of 2020-02-28. For the most up-to-date information, search www.ema.europa.eu/ema.

EGFR p.(L858R) c.2573T>G

afatinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2020-02-13 **Variant class:** EGFR L858R mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf

bevacizumab (Allergan) + erlotinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2019-11-12 **Variant class:** EGFR L858R mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/mvasi-epar-product-information_en.pdf

bevacizumab + erlotinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2020-02-20 **Variant class:** EGFR L858R mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf

dacomitinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2019-06-05 **Variant class:** EGFR L858R mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/vizimpro-epar-product-information_en.pdf

erlotinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2019-04-24 **Variant class:** EGFR L858R mutation

Reference:

https://www.ema.europa.eu/documents/product-information/tarceva-epar-product-information_en.pdf

EGFR p.(L858R) c.2573T>G (continued)

erlotinib + ramucirumab

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2020-02-25 **Variant class:** EGFR L858R mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf

gefitinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2019-05-28 **Variant class:** EGFR L858R mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/iressa-epar-product-information_en.pdf

osimertinib

Cancer type: Non-Small Cell Lung Cancer **Label as of:** 2020-02-25 **Variant class:** EGFR L858R mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf

Current ESMO Information

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated 👎 Not recommended 🛡 Resistance

ESMO information is current as of 2019-11-01. For the most up-to-date information, search www.esmo.org.

EGFR p.(L858R) c.2573T>G

● atezolizumab + bevacizumab + carboplatin + paclitaxel

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR L858R mutation

ESMO Level of Evidence/Grade of Recommendation: III / A

Population segment (Line of therapy):
- Metastatic Non-Squamous; Magnitude of Clinical Benefit Scale Score version 1.1 score: 3 (First-line therapy)
- Metastatic ; PS 0-1; Without contraindications to immunotherapy after targeted therapies have been exploited (Second-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

● afatinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

ESMO Level of Evidence/Grade of Recommendation: I / A

Population segment (Line of therapy):
- Advanced stage (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

● erlotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

ESMO Level of Evidence/Grade of Recommendation: I / A

Population segment (Line of therapy):
- Advanced stage (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

EGFR p.(L858R) c.2573T>G (continued)

gefitinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

ESMO Level of Evidence/Grade of Recommendation: I / A

Population segment (Line of therapy):
- Advanced stage (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

osimertinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

ESMO Level of Evidence/Grade of Recommendation: I / A

Population segment (Line of therapy):
- Advanced stage; ESMO-Magnitude of Clinical Benefit Scale Version 1.1 Score: 4 (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

dacomitinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

ESMO Level of Evidence/Grade of Recommendation: I / B

Population segment (Line of therapy):
- Stage IV; Magnitude of Clinical Benefit Scale Version v1.1 Score: 3 (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

erlotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFRi sensitizing mutation

ESMO Level of Evidence/Grade of Recommendation: III / B

Population segment (Line of therapy):
- Non-Squamous (Maintenance therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

EGFR p.(L858R) c.2573T>G (continued)

afatinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR activating mutation

ESMO Level of Evidence/Grade of Recommendation: I / A

Population segment (Line of therapy):
- Stage IV; PS 0-2 (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

erlotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR activating mutation

ESMO Level of Evidence/Grade of Recommendation: I / A

Population segment (Line of therapy):
- Stage IV; PS 0-2 (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

gefitinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR activating mutation

ESMO Level of Evidence/Grade of Recommendation: I / A

Population segment (Line of therapy):
- Stage IV; PS 0-2 (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

gefitinib + carboplatin + pemetrexed

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR activating mutation

ESMO Level of Evidence/Grade of Recommendation: I / B

Population segment (Line of therapy):
- Advanced stage (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

EGFR p.(L858R) c.2573T>G (continued)

bevacizumab + erlotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR activating mutation

ESMO Level of Evidence/Grade of Recommendation: II / B

Population segment (Line of therapy):
- Stage IV; ESMO-Magnitude of Clinical Benefit Scale Version 1.1 Score: 3 (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

bevacizumab + gefitinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR activating mutation

ESMO Level of Evidence/Grade of Recommendation: II / B

Population segment (Line of therapy):
- Stage IV; ESMO-Magnitude of Clinical Benefit Scale Version 1.1 Score: 3 (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

erlotinib + ramucirumab

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR activating mutation

ESMO Level of Evidence/Grade of Recommendation: II / B

Population segment (Line of therapy):
- Stage IV (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

afatinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR activating mutation

ESMO Level of Evidence/Grade of Recommendation: III / A

Population segment (Line of therapy):
- Stage IV; PS 3-4 (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

EGFR p.(L858R) c.2573T>G (continued)

dacomitinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR activating mutation

ESMO Level of Evidence/Grade of Recommendation: III / A

Population segment (Line of therapy):
- Stage IV; PS 3-4 (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

erlotinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR activating mutation

ESMO Level of Evidence/Grade of Recommendation: III / A

Population segment (Line of therapy):
- Stage IV; PS 3-4 (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

gefitinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** EGFR activating mutation

ESMO Level of Evidence/Grade of Recommendation: III / A

Population segment (Line of therapy):
- Stage IV; PS 3-4 (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Ann Oncol (2018) 29 (suppl 4): iv192–iv237; https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer]

Signatures

Testing Personnel:

Shin-Ying Lin 2020.07.24 17:37:52 +08'00'

Laboratory Supervisor:

2020.07.24 17:38:09 +08'00'

Pathologist:

Yi-Chu Yeh 2020.07.24 17:38:23 +08'00'

References

1. Lu et al. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol. Rev. 2006 Dec;58(4):782-97. PMID: 17132855
2. Davey et al. Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin Biochem Rev. 2016 Feb;37(1):3-15. PMID: 27057074
3. Crumbaker et al. AR Signaling and the PI3K Pathway in Prostate Cancer. Cancers (Basel). 2017 Apr 15;9(4). PMID: 28420128
4. Leung et al. Non-Genomic Actions of the Androgen Receptor in Prostate Cancer. Front Endocrinol (Lausanne). 2017 Jan 17;8:2. PMID: 28144231
5. Waltering et al. Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol. Cell. Endocrinol. 2012 Sep 5;360(1-2):38-43. PMID: 22245783
6. Antonarakis et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 2014 Sep 11;371(11):1028-38. PMID: 25184630
7. Zhu et al. Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur. Urol. 2018 May;73(5):727-735. PMID: 28866255
8. https://www.businesswire.com/news/home/20160106006206/en/Innocrin-Pharmaceuticals-Granted-Fast-Track-Designation-FDA
9. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202379s027s028lbl.pdf
10. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203415s015lbl.pdf
11. Lallous et al. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol. 2016 Jan 26;17:10. PMID: 26813233
12. Robinson et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015 May 21;161(5):1215-1228. PMID: 26000489
13. King et al. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985 Sep 6;229(4717):974-6. PMID: 2992089
14. ErbB Receptors and Cancer. Methods Mol. Biol. 2017;1652:3-35. PMID: 28791631
15. Gutierrez et al. HER2: biology, detection, and clinical implications. Arch. Pathol. Lab. Med. 2011 Jan;135(1):55-62. PMID: 21204711
16. Pines et al. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett. 2010 Jun 18;584(12):2699-706. PMID: 20388509
17. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014 Jul 31;511(7511):543-50. doi: 10.1038/nature13385. Epub 2014 Jul 9. PMID: 25079552
18. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 2013 Oct;45(10):1113-20. PMID: 24071849
19. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012 May;2(5):401-4. PMID: 22588877
20. da et al. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6:49-69. doi: 10.1146/annurev-pathol-011110-130206. PMID: 20887192
21. Arcila et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol. Cancer Ther. 2013 Feb;12(2):220-9. PMID: 23371856
22. Kobayashi et al. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clin Cancer Res. 2015 Dec 1;21(23):5305-13. doi: 10.1158/1078-0432.CCR-15-1046. Epub 2015 Jul 23. PMID: 26206867
23. Yasuda et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013 Dec 18;5(216):216ra177. PMID: 24353160
24. Chiu et al. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. J Thorac Oncol. 2015 May;10(5):793-9. PMID: 25668120
25. Karachaliou et al. KRAS mutations in lung cancer. Clin Lung Cancer. 2013 May;14(3):205-14. PMID: 23122493

References (continued)

26. Brennan et al. The somatic genomic landscape of glioblastoma. Cell. 2013 Oct 10;155(2):462-77. PMID: 24120142
27. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015 Jan 29;517(7536):576-82. PMID: 25631445
28. Mitsudomi et al. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010 Jan;277(2):301-8. PMID: 19922469
29. Ji et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2006 May 16;103(20):7817-22. PMID: 16672372
30. Gazdar. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009 Aug;28 Suppl 1:S24-31. PMID: 19680293
31. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf
32. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf
33. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206995s003lbl.pdf
34. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208065s013lbl.pdf
35. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf
36. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125084s273lbl.pdf
37. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125147s207lbl.pdf
38. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf
39. NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2020]
40. Peschard et al. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J. Biol. Chem. 2004 Jul 9;279(28):29565-71. PMID: 15123609
41. Peschard et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell. 2001 Nov;8(5):995-1004. PMID: 11741535
42. Abella et al. Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol. Cell. Biol. 2005 Nov;25(21):9632-45. PMID: 16227611
43. Sierra et al. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S21-35. PMID: 22128285
44. Mo et al. Targeting MET in cancer therapy. Chronic Dis Transl Med. 2017 Sep;3(3):148-153. PMID: 29063069
45. Frampton et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015 Aug;5(8):850-9. PMID: 25971938
46. Schrock et al. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. J Thorac Oncol. 2016 Sep;11(9):1493-502. PMID: 27343443
47. Pilotto et al. MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. Ann Transl Med. 2017 Jan;5(1):2. doi: 10.21037/atm.2016.12.33. PMID: 28164087
48. Reungwetwattana et al. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. Lung Cancer. 2017 Jan;103:27-37. PMID: 28024693
49. Saffroy et al. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Oncotarget. 2017 Jun 27;8(26):42428-42437. PMID: 28418914
50. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014 Sep 11;513(7517):202-9. doi: 10.1038/nature13480. Epub 2014 Jul 23. PMID: 25079317
51. Yeh et al. Activating MET kinase rearrangements in melanoma and Spitz tumours. Nat Commun. 2015 May 27;6:7174. doi: 10.1038/ncomms8174. PMID: 26013381
52. Bao et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res. 2014 Nov;24(11):1765-73. PMID: 25135958

References (continued)

53. International Cancer Genome Consortium PedBrain Tumor Project. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat. Med. 2016 Nov;22(11):1314-1320. PMID: 27748748
54. Zeng et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 2008 Jul 8;265(2):258-69. PMID: 18395971
55. Tsugawa et al. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology. 1998 Sep-Oct;55(5):475-81. PMID: 9732228
56. Di et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res. 1995 Feb;1(2):147-54. PMID: 9815967
57. https://www.novartis.com/news/media-releases/novartis-investigational-lung-cancer-therapy-capmatinib-inc280-granted-fda-breakthrough-therapy-designation-patients-met-mutated-advanced-non-small-cell-lung
58. https://www.emdgroup.com/en/news/tepotinib-breakthrough-therapy-designation-11-09-2019.html
59. Bean et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U.S.A. 2007 Dec 26;104(52):20932-7. PMID: 18093943
60. Chen et al. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res. 2009 Dec;15(4):651-8. doi: 10.1007/s12253-009-9167-8. Epub 2009 Apr 21. PMID: 19381876
61. Suda et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin. Cancer Res. 2010 Nov 15;16(22):5489-98. PMID: 21062933
62. Zhang et al. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. J Cancer Res Ther. 2016 Dec;12(Supplement):C131-C137. PMID: 28230005
63. Nguyen et al. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009 Jul;10(4):281-9. PMID: 19632948
64. Choueiri et al. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. J. Clin. Oncol. 2017 Sep 10;35(26):2993-3001. PMID: 28644771